donecopride

a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment; structure in first source

Also Known As:

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Boulouard, Michel: 3 articles (01/2020 - 09/2014)
2.	Claeysen, Sylvie: 3 articles (01/2020 - 09/2014)
3.	Dallemagne, Patrick: 3 articles (01/2020 - 09/2014)
4.	Freret, Thomas: 3 articles (01/2020 - 09/2014)
5.	Gaven, Florence: 3 articles (01/2020 - 09/2014)
6.	Giannoni, Patrizia: 3 articles (01/2020 - 09/2014)
7.	Lecoutey, Cédric: 3 articles (01/2020 - 09/2014)
8.	Rochais, Christophe: 3 articles (01/2020 - 09/2014)
9.	Hamidouche, Katia: 2 articles (01/2020 - 04/2015)
10.	Mignani, Serge: 2 articles (01/2020 - 09/2014)

Related Diseases

1.

Alzheimer Disease (Alzheimer's Disease) 01/01/2020 - "Donecopride, a Swiss army knife with potential against Alzheimer's disease." 01/01/2020 - "Here, we have assessed the potential therapeutic effects of donecopride in treating Alzheimer's disease (AD). " 04/09/2015 - "Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride." 09/09/2014 - "Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment."

Related Drugs and Biologics

1.	Therapeutic Uses
2.	Serotonin (5 Hydroxytryptamine)
3.	Ligands
4.	Cholinesterase Inhibitors (Anticholinesterases)
5.	Acetylcholinesterase